![[img]](https://epub.uni-regensburg.de/style/images/fileicons/application_pdf.png) | Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (2MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-777697
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.77769
Zusammenfassung
Motivated by the experience of COVID-19 trials, we consider clinical trials in the setting of an emerging disease in which the uncertainty of natural disease course and potential treatment effects makes advance specification of a sample size challenging. One approach to such a challenge is to use a group sequential design to allow the trial to stop on the basis of interim analysis results as soon ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Downloadstatistik